ESPR compared with ALOT: revenue, margins and what each company keeps, and the suppliers and customers both name

ESPREsperion Therapeutics, Inc.

Mkt capRevenueRevenue

ALOTAstroNova, Inc.

Mkt capRevenueRevenue

Compare

ESPREsperion Therapeutics, Inc.

ALOTAstroNova, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ESPR: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ESPR 7

PFEPfizersupplier

—Neopharmunlistedcustomer

—Otsuka Pharmaceuticalunlistedcustomer

—Seqirus Pty Ltd (CSL Seqirus)unlistedcustomer

3 more · ESPR chain ›

Shared 0

No shared counterparties.

Only ALOT 7

BABoeingcustomer

LMTLockheedcustomer

HONHoneywell Internationalsupplier

—Honeywellunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

supplier

3 more · ALOT chain ›

Price

rebased to 0%

ESPR, solidALOT, dashed

ESPREsperion Therapeutics, Inc.

3.19▼−0.16%· post 3.20

Mkt cap$818.6MRevenue$80MQ1 FY26Revenue$403MFY25

ALOTAstroNova, Inc.

28.99▼−0.01%· post 29.00

ClosedAug 26 '26

Mkt cap$224.6MRevenue$39MQ1 FY27Revenue$151MFY26

Compare

ClosedAug 26 '26

ESPREsperion Therapeutics, Inc.

ALOTAstroNova, Inc.

3.19▼−0.16%post 3.20

Price

28.99▼−0.01%post 29.00

$818.6M

Mkt cap

$224.6M

Q1 FY26$80M

Revenue

$39MQ1 FY27

FY25$403M

Revenue

$151MFY26

ESPR3.19▼−0.16%vsALOT28.99▼−0.01%ClosedAug 26 '26